A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

Summary

The goal of this randomized clinical trial is to learn if topical treatment with ATR04-484 can treat skin rash in patients undergoing EGFR inhibitor (EGFRi) therapy. The primary goal of the study is to determine safety and tolerability of ATR04-484, and the secondary goal of the study is to assess efficacy signals of ATR04-484. Researchers will compare treatment of ATR04-484 to its vehicle. Participants will: * Apply ATR04-484 or vehicle daily for 28 days * Visit the clinic periodically for evaluation and sample collection

Timeline

Start

2025-08-25

Primary completion

2027-01-15

Completion

2027-02-15

Drugs

Indications

No indication recorded.